Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions - Takeaways - MDSpire

Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions

  • By

  • Maen Abdelrahim

  • Abdullah Esmail

  • Bandar Al-Judaibi

  • Ola Khorshid

  • Bhoori Sherrie

  • Vincenzo Mazzaferro

  • May 28, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors (ICPIs) have shown promise in downstaging hepatocellular carcinoma (HCC) for liver transplantation (LT) eligibility.

  • 2

    The use of ICPIs around LT is complicated by a significant risk of acute graft rejection, with rates ranging from 18% to 37%.

  • 3

    Optimal washout periods of 50 to 90 days and intensified immunosuppression can help mitigate rejection risks post-transplant.

  • 4

    Living donor LT offers scheduling flexibility, which can enhance the timing of ICPIs in the transplant process.

  • 5

    Emerging biomarkers and surveillance strategies are essential for risk stratification in patients receiving ICPIs during the transplant journey.

Original Source(s)

Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions

  • by Maen Abdelrahim, Abdullah Esmail, Bandar Al-Judaibi, Ola Khorshid, Bhoori Sherrie, Vincenzo Mazzaferro

  • May 28, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

High-grade astrocytoma with piloid features: a case report of comprehensive management

Synthetic short RNA in cancer